Introduction
Burkholderia (formerly Pseudomonas) pseudomallei is an environmental Gram-negative bacillus which is the cause of melioidosis, a potentially fatal infection of humans. Choice of treatment for this infection is limited because of the organism's resistance to aminoglycosides and the relatively poor activity of the fluoroquinolone compounds . Treatment with ceftazidime has reduced the mortality to approximately 40% ) and a recent trial has shown that high dose co-amoxiclav has achieved a similar reduction in mortality (Suputtamongkol et al., 1994) . However strains with resistance to one or both of these /Mactam antibiotics have emerged during treatment .
Previous studies have shown that imipenem is one of the most active antibiotics against B. pseudomallei. In this study we have evaluated imipenem and other new carbapenem antibiotics for in-vitro activity against B. pseudomallei, including strains with reduced susceptibility or resistance to ceftazidime and co-amoxiclav.
Materials and methods

Bacterial strains
Strains of B. pseudomallei, used in this study, were isolated from patients in Ubon Ratchatani, north-eastern Thailand. MICs were performed on 100 consecutive strains isolated during 1991-1992. Two of these strains were resistant to chloramphenicol and one strain was resistant to ceftazidime by disc diffusion. The remaining 97 strains were susceptible to the normal range of antibiotics with known activity against B. pseudomallei . Twenty of these strains were randomly selected for subsequent determination of MBCs.
Subsequently, MICs and MBCs were determined for 24 strains of B. pseudomallei with reduced susceptibility or resistance to ceftazidime and/or co-amoxiclav (MIC ^ 16mg/L for both antibiotics). Reduced susceptibility to ceftazidime alone occurred in seven strains, to co-amoxiclav alone in seven strains, and to both antibiotics in ten strains. These strains have been collected since 1987, following the introduction of these antibiotics for the treatment of melioidosis.
Three strains of B. pseudomallei were then selected for time-kill kinetic studies. These were 576a (normal susceptibility pattern), 704f (resistant to co-amoxiclav) and 979b (MIC = 256 mg/L for both ceftazidime and co-amoxiclav).
Antimicrobial agents
The antibiotics used in this study were gifts from the manufacturers: amoxycillin, clavulanic acid (SmithKline Beecham Pharmaceuticals, UK), biapenem (Lederle Laboratories, UK), ceftazidime (Glaxo Laboratories Ltd., UK), imipenem (Merck Sharp & Dohme Ltd., UK), meropenem (ICI Pharmaceuticals, UK), panipenem (Sankyo Co. Ltd., Japan).
Susceptibility tests
MICs were determined by an agar dilution method following NCCLS guidelines (1993), and MBCs were determined by a microtitre dilution method using Mueller-Hinton broth, as described previously .
Time-kill kinetic studies were performed in Mueller-Hinton broth with a starting inoculum of approximately 5 x 10 5 cfu/mL, as described previously . Antibiotics were used at a concentration of 4 x MIC for each strain. Bactericidal activity was defined as ^3 log, 0 reduction from the starting inoculum. 
Results and discussion
The MIC and MBC results for 100 consecutive strains of B. pseudomallei are given in Table I . These strains were all fully susceptible to co-amoxiclav. One strain was resistant to ceftazidime (MIC = 32 mg/L). All strains were susceptible to each of the four carbapenems, with MIG» values lower than those for ceftazidime or co-amoxiclav. Twenty strains were randomly selected for MBC determination; these did not include the ceftazidime resistant strain. The MBC™ values for the carbapenems were ;> 4-fold lower than ceftazidime or co-amoxiclav. Of the four carbapenem antibiotics, biapenem was the most active against B. pseudomallei. Yamamoto et al. (1990) also found that imipenem, meropenem and panipenem had good activity against B. pseudomallei, although they did not test biapenem, nor did they determine MBCs. The MIC and MBC results for 24 strains of B. pseudomallei with reduced susceptibility or resistance to ceftazidime and/or co-amoxiclav are shown in Table II . The carbapenems retained their bactericidal activity. Biapenem was the most active of the four carbapenems. Imipenem and meropenem had equivalent activities against most strains. Although the MICs for panipenem were higher than the other carbapenems they are still considered to be susceptible (T. Fukuoka, Sankyo Co., personal communication). The group of strains showing reduced susceptibility to ceftazidime had significant increases in MIC to biapenem, meropenem and panipenem (Kruskal-Wallis analysis of variance, P< 0.0001) although the absolute values remained within the susceptibility range. There was no significant increase in MICs for imipenem. However, two strains resistant to both ceftazidime and co-amoxiclav had MIC values for imipenem of 8 mg/L. This is only moderately susceptibility according to NCCLS guidelines, however the MBCs for imipenem were also 8 mg/L, and they remained fully susceptible to the other carbapenems.
Time-kill studies for imipenem and meropenem against the susceptible strain 576a and the co-amoxiclav resistant strain 704f have been published previously . In the present study these were extended to include biapenem and panipenem, and a third strain of B. pseudomallei (979b) resistant to ceftazidime and co-amoxiclav. The MICs for the three test strains (576a, 704f and 979b) to biapenem were 0.25, 1, 1 mg/L respectively; to imipenem 1, 2, 0.5 mg/L; to meropenem 2, 2, 4 mg/L and to panipenem 0.5, 8 and 2 mg/L respectively. All time-kill studies used antibiotic concentrations of 4 x MIC. Biapenem and panipenem were significantly bactericidal for strains 576a and 704f; biapenem within 4 h (similar to imipenem) and panipenem within 6 h (similar to meropenem). In time-kill studies using strain 979b all four carbapenems were significantly bactericidal within 4 h. In contrast, our previous study showed that co-amoxiclav was not bactericidal when tested against the sensitive strain 576a and ceftazidime was not bactericidal for either 576a or 704f.
B. pseudomallei is unusual among "pseudomonads" in that it produces a Richmond & Sykes Class I /f-lactamase which is inhibited by clavulanic acid (Livermore et al., 1987) . Godfrey et al. (1991) have shown three different mechanisms of /Mactam resistance in B. pseudomallei which may result in resistance to co-amoxiclav, ceftazidime or both antibiotics. Insensitivity of the chromosomal /J-lactamase to clavulanic acid and alteration of the enzyme resulting in specific hydrolysis of ceftazidime alone would not be expected to reduce susceptibility to the carbapenems. Derepression of this chromosomal /J-lactamase produces resistance to both ceftazidime and co-amoxiclav, but this study shows that it does not significantly reduce susceptibility to carbapenems. Chen & Livermore (1994) have shown that the carbapenems overcome the mechanisms, especially /Mactamase production, that commonly produce resistance in Pseudomonas aeruginosa to other classes of anti-pseudomonal jS-lactams.
The data in our study confirm that the carbapenems are the most active antibiotics against B. pseudomallei. In general, they retain bactericidal activity against strains resistant to ceftazidime and co-amoxiclav (the current treatments of choice for severe melioidosis), although MICs and MBCs are higher than for susceptible strains. The carbapenems are indicated for treatment of infection with these resistant strains; although expensive, imipenem is currently available for use within Thailand. Unfortunately, biapenem, the most active antibiotic against B. pseudomallei has been withdrawn from further development.
A comparative trial is now needed to determine if the carbapenems will be a significant improvement in the treatment of all patients with severe melioidosis. However, it is possible that increased use of the carbapenems will lead to the development of resistance, as has happened with the use of ceftazidime and co-amoxiclav.
